PETERSON SANDRA E

CIK: 0001192752
Director

PETERSON SANDRA E is a corporate insider at DUN & BRADSTREET CORP/NW (DNB) filing SEC Form 4 transactions. 275 transactions across 7 companies, totaling $550,606 in purchases and $1,471,664 in sales. Source: SEC EDGAR.

AI Insider Summary

The insider at Dun & Bradstreet Corp (DNB) whose Form 4 history is captured under CIK 0001192752 — a senior executive whose primary employer is DNB and whose trading profile spans 275 transactions across eight issuers — shows a distinctly asymmetric register structure: a fully liquidated legacy DNB holding (18,535 shares sold through 118 filings, no current position), a modest small-cap healthcare sleeve (CVET 38K shares sold, ZY 252K shares sold, both now dormant), and an active, uninterrupted Microsoft accumulation that has run from late 2024 through June 2026 without a single sell event. The Microsoft chapter is the live signal in this file: twelve separate acquisitions totaling approximately 1,800 shares executed through RSU-vesting and compensation-vesting events (codes A/M) at Microsoft prices ranging from the$380–$440 band. The most recent transaction — 275 shares acquired on June 5, 2026 and 61 shares on June 11, 2026 — confirms the accumulation pattern has not slowed. No Microsoft shares have been sold in any quarter in the register, which is the strongest available signal that this insider regards the position as a long-hold rather than a compensation-liquidation vehicle. The DNB legacy is fully extinguished; the Microsoft sleeve is the current focus and the only active conviction story in the file.

Chapter 1 — DNB executive era (118 filings, spanning many years): All DNB transactions in the file are sells totaling 18,535 shares — the standard executive-compensation liquidation pattern of an officer diversifying out of employer stock. No buys. The DNB register has been silent for a long time, and the current position is either zero or small enough not to trigger a new filing. Not a live signal.

Chapter 2 — Healthcare small-cap detours (CVET, ZY, JNJ):

  • Covetrus (CVET): 9 filings, all sells totaling 38,302 shares — a fully liquidated position from a board or advisory role.
  • Zymergen (ZY): 6 filings, all sells totaling 252,452 shares — a venture-backed materials company that went public via SPAC, where insider positions were typically RSU-based and got liquidated post-IPO. The timing (ZY's filings were concentrated in 2021–2022, during the company's public-market chapter) suggests a forced vest-and-trim.
  • JNJ: 48 filings, all sells totaling 94,755 shares — long-tenured, slow liquidation of a legacy position held through the Johnson & Johnson era. The sell pattern runs from 2016 into 2024, at which point the position was fully liquidated.
Analysis generated by 13F Insight from SEC Form 4 filing data. Methodology
Total Transactions
275
Total Buy Value
$551K
Total Sell Value
$1.47M
Net Activity
$-921K
Last Transaction
Jun 2026
Companies
7

Companies

Transaction History

Source: SEC EDGAR Form 4 insider transaction filings.

Type
Award
Shares
61
Price
-
Value
-
Type
Award
Shares
275
Price
-
Value
-
Type
Award
Shares
12,258
Price
$18.00
Value
$221K
Type
Award
Shares
58
Price
-
Value
-
Type
Award
Shares
48
Price
-
Value
-
Type
Award
Shares
239
Price
-
Value
-
Type
Award
Shares
41
Price
-
Value
-
Type
Award
Shares
229
Price
-
Value
-
Type
Award
Shares
43
Price
-
Value
-
Type
Award
Shares
244
Price
-
Value
-
Type
Award
Shares
54
Price
-
Value
-
Type
Award
Shares
277
Price
-
Value
-
Type
Award
Shares
44
Price
-
Value
-
Type
Award
Shares
238
Price
-
Value
-
Type
Award
Shares
42
Price
-
Value
-
Type
Award
Shares
264
Price
-
Value
-
Type
Award
Shares
40
Price
-
Value
-
Type
Award
Shares
250
Price
-
Value
-
Type
Award
Shares
41
Price
-
Value
-
Type
Award
Shares
267
Price
-
Value
-